文献速递复苏、休克与脓毒症消化、代谢与肾脏急症重症综合管理与镇静镇痛

严重休克患者非闭塞性肠系膜缺血动脉内血管扩张治疗的应答预测因素:前瞻性观察研究结果

Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study.
PubMed 文献 · Crit Care · 2022-04-04
一句话结论严重休克合并NOMI患者接受动脉内前列腺素治疗后,24小时乳酸下降>2 mmol/l与28天死亡率降低相关(HR 0.409)。

这项前瞻性单中心观察研究纳入42例严重休克合并非闭塞性肠系膜缺血(NOMI)患者,接受动脉内血管扩张剂(前列腺素)治疗,主要终点为24小时血乳酸较基线下降>2 mmol/l,关键次要终点为28天死亡率。结果显示乳酸从基线9.2 mmol/l降至24小时4.4 mmol/l(p<0.001),22例(52.4%)达到主要终点;基线乳酸较高和去甲肾上腺素剂量较低是缺血改善的独立预测因素。24小时乳酸下降>2 mmol/l者28天死亡率为59%,其余患者为85%(HR 0.409;95%CI 0.14-0.631,p=0.005)。作者认为这些结果可能有助于设计随机对照试验进一步研究该治疗策略。

要点

  • 42例严重休克合并NOMI患者接受动脉内前列腺素治疗,24小时乳酸由基线9.2 mmol/l降至4.4 mmol/l(p<0.001)。
  • 22例(52.4%)在干预后24小时达到乳酸下降>2 mmol/l的主要终点。
  • 24小时乳酸下降>2 mmol/l者28天死亡率为59%,其余患者为85%(HR 0.409;95%CI 0.14-0.631,p=0.005)。
  • 基线乳酸较高和去甲肾上腺素剂量较低是缺血改善的独立预测因素。
  • 作者认为该结果可能有助于设计随机对照试验进一步研究动脉内前列腺素治疗NOMI。

适用人群与场景

  • 严重休克合并非闭塞性肠系膜缺血(NOMI)患者,纳入时去甲肾上腺素剂量中位数0.37(IQR 0.21-0.60)μg/kg/min,乳酸9.2(IQR 5.2-13)mmol/l,伴多器官衰竭。

诊断标准与关键阈值

  • 缺血改善(主要终点)定义为干预后24小时血乳酸较基线下降>2 mmol/l。

处置流程与药物剂量

  • 动脉内输注前列腺素进行血管扩张治疗。

研究设计与关键结果

  • 前瞻性单中心观察研究,共纳入42例严重休克合并NOMI接受动脉内血管扩张治疗的患者。
  • 乳酸从基线9.2(IQR 5.2-13)mmol/l降至24小时4.4(IQR 2.5-9.1)mmol/l,p<0.001;22例(52.4%)在24小时达到乳酸下降>2 mmol/l。
  • 基线乳酸较高和去甲肾上腺素剂量较低是缺血改善的独立预测因素。
  • 24小时乳酸下降>2 mmol/l者28天死亡率为59%,其余患者为85%(HR 0.409;95%CI 0.14-0.631,p=0.005)。

证据类型、等级与局限

  • 证据类型:前瞻性单中心观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,关于NOMI患者接受动脉内前列腺素治疗结局预测因素的发现,可能有助于设计随机对照试验以进一步研究该治疗策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Non-occlusive mesenteric ischemia (NOMI) is a life-threatening condition occurring in patients with shock and is characterized by vasoconstriction of the mesenteric arteries leading to intestinal ischemia and multi-organ failure. Although minimal invasive local intra-arterial infusion of vasodilators into the mesenteric circulation has been suggested as a therapeutic option in NOMI, current knowledge is based on retrospective case series and it remains unclear which patients might benefit. Here, we prospectively analyzed predictors of response to intra-arterial therapy in patients with NOMI.

METHODS: This is a prospective single-center observational study to analyze improvement of ischemia (indicated by reduction of blood lactate > 2 mmol/l from baseline after 24 h, primary endpoint) and 28-day mortality (key secondary endpoint) in patients with NOMI undergoing intra-arterial vasodilatory therapy. Predictors of response to therapy concerning primary and key secondary endpoint were identified using a) clinical parameters as well as b) data from 2D-perfusion angiography and c) experimental biomarkers of intestinal injury.

RESULTS: A total of 42 patients were included into this study. At inclusion patients had severe shock, indicated by high doses of norepinephrine (NE) (median (interquartile range (IQR)) 0.37 (0.21-0.60) μg/kg/min), elevated lactate concentrations (9.2 (5.2-13) mmol/l) and multi-organ failure. Patients showed a continuous reduction of lactate following intra-arterial prostaglandin infusion (baseline: (9.2 (5.2-13) mmol/l vs. 24 h: 4.4 (2.5-9.1) mmol/l, p < 0.001) with 22 patients (52.4%) reaching a lactate reduction > 2 mmol/l at 24 h following intervention. Initial higher lactate concentrations and lower NE doses at baseline were independent predictors of an improvement of ischemia. 28-day mortality was 59% in patients with a reduction of lactate > 2 mmol/l 24 h after inclusion, while it was 85% in all other patients (hazard ratio 0.409; 95% CI, 0.14-0.631, p = 0.005).

CONCLUSIONS: A reduction of lactate concentrations was observed following implementation of intra-arterial therapy, and lactate reduction was associated with better survival. Our findings concerning outcome predictors in NOMI patients undergoing intra-arterial prostaglandin therapy might help designing a randomized controlled trial to further investigate this therapeutic approach. Trial registration Retrospectively registered on January 22, 2020, at clinicaltrials.gov (REPERFUSE, NCT04235634), https://clinicaltrials.gov/ct2/show/NCT04235634?cond=NOMI&draw=2&rank=1 .

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Rittgerodt N, Pape T, Busch M, et al. Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study. Crit Care. 2022. PMID: 35379286. doi:10.1186/s13054-022-03962-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。